Financial summary
Cancer Research Horizons has a range of income streams and spending commitments. Here we breakdown our financial activity from 2022/23.
Continue
Cancer Research Horizons financial activity
£79m
Total gross income
£26m
Distributions to partners
£34m
Other operating costs
£22m
Reinvested in Cancer Research UK after tax adjustment
Income
Key royalty streams
£59m
Therapeutic Innovation
£11m
Other licensing activities
£2m
Reagents business
£7m
Other income
£0.8m
Total income
£79m
Expenditure
Distributions to partners
£26m
Staff costs
£16m
Patent expenditure
£1m
Investment in entrepreneurship
£0.5m
Other operating costs
£17m
Total expenditure
£61m
